Beximco Pharmaceuticals PLC. Share Price
Stocks
BXPHARMA
BD0453BXPH04
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Dhaka S.E.
24/09/2026
|
5-day change | 1st Jan Change | ||
| 148.40 BDT | -0.67% |
|
-0.20% | +45.35% |
| 09-15 | Beximco Pharmaceuticals Confirms Reports of Potential Board Changes | MT |
| 06-26 | Beximco suspension lifted; M1 payment date extension | AN |
| Market Cap | 66.2B 536M 472M 444M 406M 758M 51.46B 764M 5.33B 2.07B 26.19B 2.01B 1.97B 85.22B | P/E 2026 * |
7.64x | P/E 2027 * | 6.68x |
|---|---|---|---|---|---|
| Enterprise Value | 66.2B 536M 472M 444M 406M 758M 51.46B 764M 5.33B 2.07B 26.19B 2.01B 1.97B 85.22B | EV / Sales 2026 * |
1.21x | EV / Sales 2027 * | 1.08x |
| Free-Float |
85.91% | Yield 2026 * |
4.06% | Yield 2027 * | 4.64% |
| 1 day | -0.67% | ||
| 1 week | -0.20% | ||
| Current month | +2.13% | ||
| 1 month | +2.91% | ||
| 3 months | +1.71% | ||
| 6 months | +25.98% | ||
| Current year | +45.35% |
| 1 week | 146 |  | 151.1 |
| 1 month | 143 | | 154.5 |
| Current year | 99.5 | | 158.5 |
| 1 year | 99.5 | | 158.5 |
| 3 years | 64.2 | | 158.5 |
| 5 years | 64.2 | | 255.4 |
| 10 years | 47.36 | | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 03/03/2024 |
| Director of Finance/CFO | 63 | 31/12/2002 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 18/06/2009 | |
| Director/Board Member | - | 31/01/2010 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 31/12/1984 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.67% | -0.20% | +29.27% | +1.50% | 541M | |
| +2.68% | +2.56% | +59.32% | +114.00% | 1,026B | |
| +0.56% | +0.17% | +53.19% | +68.90% | 649B | |
| +0.02% | +0.42% | +20.51% | +71.43% | 468B | |
| +0.06% | +0.25% | +37.03% | +45.71% | 352B | |
| +1.16% | +4.10% | +21.99% | +29.39% | 271B | |
| -0.24% | +2.18% | +10.14% | +12.26% | 256B | |
| -0.01% | +6.91% | +45.42% | +52.15% | 220B | |
| -1.11% | -0.80% | +31.69% | +100.04% | 188B | |
| +0.30% | -7.19% | -32.43% | -60.56% | 170B | |
| Average | +0.37% | +1.18% | +27.61% | +43.48% | 359.96B | |
| Weighted average by Cap. | +1.07% | +1.25% | +38.06% | +67.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.78B 444M 390M 368M 336M 628M 42.58B 632M 4.41B 1.71B 21.67B 1.67B 1.63B 70.52B | 61.27B 496M 436M 411M 375M 702M 47.62B 707M 4.94B 1.91B 24.24B 1.86B 1.82B 78.87B |
| Net income | 8.66B 70.14M 61.69M 58.16M 53.06M 99.23M 6.73B 100M 698M 270M 3.43B 263M 258M 11.15B | 9.92B 80.32M 70.65M 66.6M 60.76M 114M 7.71B 115M 799M 310M 3.92B 302M 295M 12.77B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/09/26 | BDT 148.40 | -0.67% | 349,479 |
| 23/09/26 | BDT 149.40 | +0.40% | 1,730,765 |
| 22/09/26 | BDT 148.80 | +1.64% | 521,197 |
| 21/09/26 | BDT 146.40 | -0.88% | 463,427 |
| 20/09/26 | BDT 147.70 | +0.34% | 439,357 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
